XML 33 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions
 6 Months Ended
Jun. 30, 2020
Related Party Transactions [Abstract]  
Related Party Transactions

8.

Related Party Transactions

Astellas is an equity investor in the Company and considered a related party. The Company recorded revenue related to collaboration agreements with Astellas of $4.8 million and $134.7 million for the three months ended June 30, 2020 and 2019, respectively, and $9.5 million and $139.6 million for the six months ended June 30, 2020 and 2019, respectively.  For the three and six months ended June 30, 2020, the Company also recorded $8.2 million drug product revenue from Astellas.  

The Company recorded expense related to collaboration agreements with Astellas of $0.2 million and $0.8 million during the three months ended June 30, 2020 and 2019, respectively, and $0.3 million and $1.3 million during the six months ended June 30, 2020 and 2019, respectively.

As of June 30, 2020 and December 31, 2019, accounts receivable from Astellas were $12.1 million and $4.8 million, respectively, and amounts due to Astellas were $0.2 million and $36.9 million, respectively. The amounts due to Astellas as of December 31, 2019 included $36.3 million of a change in estimated variable consideration related to the API product revenue recognized in 2018, at the time the roxadustat listed price was issued by the Japanese Ministry of Health, Labour and Welfare. Such amount was fully paid during the first quarter of 2020.

Prepaid expenses and other current assets as of December 31, 2019 included $125.2 million of net unbilled contract assets, respectively, representing a $130.0 million unbilled contract asset related to two regulatory milestones under the Europe Agreement with Astellas associated with the planned MAA submission to the EMA, net of $4.8 million of associated deferred revenue. According to the Europe Agreement, this $130.0 million was billed to Astellas upon the submission of an MAA in the second quarter of 2020. See Note 2 for details.